Battelle, Pacific Northwest National Laboratories (PNNL), P.O. Box 999, (MSIN K3-04), Richland, WA 99352

A -- DEVELOPMENT AND COMMERCIALIZATION OF THREE RADIOISOTOPE RELATED TECHNOLOGIES. POC Michael Lind phone (206) 528-3203 or E-Mail michael.lind@pnl.gov The Pacific Northwest National Laboratory is seeking interested parties to assist in the development and commercialization three radioisotope related technologies. Microbial Synthesis of Technetium for Pharmaceuticals. This is a new patented pending microbial process to produce technetium compounds used in medical imaging and diagnosis. The new process eliminates problems of contamination resulting from inorganic chemical reduction of technetium and offers the potential for synthesis of new compounds of different oxidation states. The process is being developed for delivery to the end user in a simple kit form. Small Automated Medical Isotope Generator for Bi-213 Production. A small, closed, versatile, automated isotope generator platform has been developed using improved chemistries for the production of medical isotopes in commercial settings as well as medical clinics and hospitals. High precision computer controlled microfluidics are used to integrate the required solution handling steps of the novel anion exchange separation chemistries to produce high purity Bi-213 while minimizing the waste. While emphasis has been placed on milking an Ac-225 cow to produce the short lived alpha emitter B-213 using this tandem column generator, other chemistries for Re-188, Tc-99 and Ra-223 are possible. Extraction of high purity Y-90 from Sr-90. Improved separation chemistry and an automated separations process promises low transition metal impurities and hence better protein labeling capacity for the medical applications of the Y-90 beta emitter. The tandem column generator process under development at the laboratory uses a miniature sorbent column to separate Y-90 from Sr-90 in a stock load/recovery and scrub column followed by a polishing column to capture the remaining impurities. The new chemistry is expected to represent a significant improvement over current solvent extraction technology. Those firms interested in teaming with the laboratory to develop and commercialize one or more of the above technologies are encouraged to telephone or e-mail a statement of interest to Michael Lind 206/528-3203 michael.lind@pnl.gov within one week of this notice. Posted 07/21/99 (W-SN357379). (0202)

Loren Data Corp. http://www.ld.com (SYN# 0002 19990723\A-0002.SOL)